PlainRecalls
FDA Drug Critical Class I Terminated

Rhino 7 Platinum 30000 Capsules, in blue,orange,black background with red,white,blue,gray text in hologram paper packaging, packaged in 2, 4, and 10 count blister cards, Motto International, Dallas, TX

Reported: January 22, 2020 Initiated: December 17, 2019 #D-0656-2020

Product Description

Rhino 7 Platinum 30000 Capsules, in blue,orange,black background with red,white,blue,gray text in hologram paper packaging, packaged in 2, 4, and 10 count blister cards, Motto International, Dallas, TX

Reason for Recall

Marketed without an Approved NDA/ANDA; FDA analysis found product to contain tadalfil

Details

Recalling Firm
Motto International Corp
Units Affected
5 boxes
Distribution
TX
Location
Dallas, TX

Frequently Asked Questions

What product was recalled?
Rhino 7 Platinum 30000 Capsules, in blue,orange,black background with red,white,blue,gray text in hologram paper packaging, packaged in 2, 4, and 10 count blister cards, Motto International, Dallas, TX. Recalled by Motto International Corp. Units affected: 5 boxes.
Why was this product recalled?
Marketed without an Approved NDA/ANDA; FDA analysis found product to contain tadalfil
Which agency issued this recall?
This recall was issued by the FDA Drug on January 22, 2020. Severity: Critical. Recall number: D-0656-2020.